Good morning.
Futures mixed after a messy Q3 opener. S&P flat-ish, NDX -1.5%, but IGV +3% — violent rotation out of semis into software. META +10% on cloud pivot news, adding $150B in market cap. Neoclouds crushed: NBIS -17%, CRWV -14%. MU -10.6% on no bad news — just positioning unwinds in memory. Asia: China semi regulators tapping the brakes — 60+ companies issued risk warnings, insider selling at record. Apple exploring memory buys from YMTC/CXMT, risking national security blowback. Fed's Warsh sounded dovish, ADP missed at 98k vs 120k, ISM prices paid collapsed. Rate cut probability ticks up.
Three themes framing today. One, Meta's capex hedge is real — they're building a cloud business to absorb $125-145B in spend, validating hyperscaler capex while putting a ceiling on neocloud margins. Two, memory is tightening (BofA raises SNDK PT, GM signs SCA with MU) but stocks got slaughtered — that's a positioning problem, not a fundamental one. Watch for dip buyers. Three, the factor rotation out of AI/semis into software is the biggest in a decade — IGV vs SOXX spread widened 12% in a single session. This could have legs if macro keeps softening.
We'll hit up META and PANW first, then get to semis and software.
Verdict: The Brookfield expansion is incrementally positive but the stock price has already lapped the narrative. The $25B framework ($20B incremental on top of the original $5B) is a real signal of institutional conviction and a genuine demand catalyst. But the stock is at $302, the street PT range tops out at $350 (UBS), and the consensus view is clearly cautious. PMs need to decide: is this a high-beta AI infrastructure winner still re-rating, or a story where most of the good news is already in the tape?
Four articles, one headline: Brookfield just threw another $20B of financing capacity at Bloom Energy's AI-fuel-cell thesis. The partnership framework went from $5B to $25B, funded through Brookfield's $100B AI Infrastructure Fund. The stock has done 1,268% in the past year. Current market cap: ~$86B.
The analyst scorecard tells you everything about the divergence between price and fundamental comfort:
What's new: The $20B incremental commitment is real and structural. This isn't a press release — it's an active joint venture that already generated $1.2B in product revenue from Phase 1. Brookfield is putting $100B behind this. The regulatory tailwind from FERC's transmission queue reform (cited by UBS) is a real accelerator for data center build timelines.
What was already known: The partnership existed. The AI infrastructure demand surge is well-telegraphed. The stock's 1,268% move reflects these expectations.
The critical incremental data point: Wells Fargo estimates the new $20B implies ~$6B revenue opportunity for BE at a 25-30% capture rate, or $1-2B in annual revenue over 3-5 years. Their math says that's worth $23-$52/share. That's not nothing — but they also note the current price already discounts 19 GW of orders.
"The current stock price already discounts 19 gigawatts of orders, implying most of this upside could already be priced in." > — Wells Fargo
That's the bear case in one line.
Bull (UBS framing): The Brookfield expansion validates the thesis that AI factories need to integrate power, compute, and capital from day one. Bloom's fuel-cell advantage (time-to-power, DC architecture, modularity) is a unique solution to a ~100% y/y increase in data center power demand. The FERC rule change on transmission queue access is a direct catalyst for faster deployment. The $20B commitment isn't a ceiling — it's a signal that Brookfield sees this as a repeatable model at scale. The CEO's new performance-based equity grant (271k shares at target, up to 3x) aligns incentives with aggressive revenue goals through 2029.
Bear (Wells Fargo / BMO framing): The math doesn't work at this price. $52/share of incremental value from $20B of new financing, against a stock at $302. The market is pricing in GM-like scale without the technology having demonstrated reliability at multi-gigawatt deployment levels. Solid oxide fuel cells at scale are unproven. BMO's three scenario cases (2.4 GW to 5.0 GW) imply a wide range of outcomes with significant execution risk. The $25B framework is a capital structure tool, not backlog. Phase 1 consumed $1.2B of $1.4B capacity — implying the new $20B could be consumed faster than expected, but that's just pulling forward revenue, not creating new demand.
Broadest: The Brookfield-BE partnership is a template for how AI infrastructure gets financed in a world where power is the binding constraint. Every hyperscaler is looking for behind-the-meter generation solutions that bypass transmission bottlenecks. The read-through is positive for other clean-tech / energy transition plays tied to data center demand (GE Vernova, NEE, CEG, TLN), but bearish for the thesis that traditional utility-scale power buildout is the only solution.
For BE specifically: The stock is pricing in a massive order flow that hasn't been proven. If BE can convert this framework into signed PPAs and actual deployments over the next 2-3 quarters, the bull case gains weight. If it's just a financing vehicle with no incremental demand visibility — the stock is a crowded long waiting for a catalyst miss.
The bottom line for PMs: This is a high-beta AI infrastructure name with real institutional backing and a stock that has massively re-rated. The fundamental story is intact but the risk/reward at $302 is asymmetrical to the downside relative to the analyst base. If you're already long, you're betting the sell-side is structurally behind the power curve. If you're not, there's no margin of safety.
Verdict: Meta Compute is the narrative pivot the stock needed. The overbuild fear is getting replaced by a monetization story — and the market is buying it. META +3% pre-market, pushing toward $640. This is the single highest-signal development for the name in months.
Three firms out this morning, all reacting to Bloomberg’s scoop that Meta is launching a cloud business (“Meta Compute”) selling excess AI compute and models. The consensus: this gives investors a visible ROI on that ~$141B in 2026 capex (BMO’s number). No one thinks it’s an AWS-killer overnight, but the direction of travel matters more than the TAM right now.
Mizuho ($835 PT) calls it “optionality” — a Plan B that adds margin of safety to medium-term EPS. They’re careful to say this isn’t a near-term business line, but the financial foundation (82% gross margin, 26% rev growth) supports the investment thesis regardless.
Jefferies ($825 PT) is the most aggressive: Brent Thill says “the overbuild narrative is backward” — Meta is late to the cloud party, not early. He frames it as following AWS’s playbook: monetize excess compute to lift utilization, improve ROIC, and fund more capex.
“Meta’s value remains intact as one of the best at hosting AI compute against a multi-trillion dollar buildout.” — Brent Thill, Jefferies
BMO ($720 PT) is incrementally positive but stays Market Perform. They note the cloud business is a “clear tailwind” to revenue and OI, but they’re waiting on size/scale details before moving their model. Fair — $720 implies only 16% upside from here.
Bull case: This is AWS 2.0. Meta has the compute, the models (Llama), and the balance sheet to build a real cloud business. Even if it takes 3-5 years, it kills the “Zuck is burning cash” narrative dead.
Bear case: The hyperscale cloud market is saturated with AWS/Azure/GCP. Meta is a late entrant with no enterprise salesforce. And if they’re just leasing out spare capacity, the revenue per watt is probably worse than what they get using it internally. This could be a low-margin distraction.
Verdict: Panic selling on a Bloomberg scoop that Meta might eventually become a competitor. Two analysts say the selloff is overdone. CoreWeave’s contracts with Meta are locked, take-or-pay, non-cancellable. Buying opportunity if you believe GPU demand stays tight. I wouldn’t chase the bottom yet, but the signal here is clear — street thinks the fear is misplaced.
Shares dropped ~14% Wednesday after Bloomberg reported Meta is developing “Meta Compute” — a plan to sell AI compute capacity and model access. The market immediately priced in a risk that CoreWeave’s biggest customer (META accounts for ~$35B of the ~$100B 1Q backlog) is turning into a rival.
Rosenblatt (Buy, $250 PT) calls the pullback a buying opportunity. Their channel checks show NO change in hyperscale GPU procurement posture — shortages remain the norm. Crucially, they argue Meta does not have the right to resell capacity leased from CoreWeave through 2032. That means existing contracts are insulated even if Meta builds out its own cloud business.
Evercore ISI (Outperform, $150 PT) echoes the thesis: zero impact to CoreWeave’s current business with Meta. They note the report is unconfirmed and that Zuck himself told shareholders in May his company hasn’t explored this model. Demand for GPU compute remains “robust and diversified across hyperscalers, frontier model labs, and enterprises.”
“The weakness in CoreWeave stock Wednesday provides a buying opportunity.” — Rosenblatt Securities
Bull case: Meta’s own cloud is years away (if it even materializes). CoreWeave’s backlog is locked in take-or-pay contracts. GPU supply is still tight — the meta narrative is a distraction, not a threat. At ~$87, the stock is pricing in a worst case that hasn’t happened.
Bear case: If Meta succeeds, it removes a major demand driver for the neocloud space and signals that hyperscalers will increasingly internalize capacity. Even if current contracts hold, future growth with Meta is capped. And if Meta starts competing on price, the whole GPU compute market gets squished.
The tape says “competitive threat.” The analysts say “zero near-term impact.” I lean with the analysts — Meta’s move is a 2028+ problem, if that. The 14% drop is a fat pitch for PMs with a 6–12 month horizon. But watch for any follow-up from Meta. If they confirm, the narrative gets stickier.
Citizens stayed at Market Perform after a 12-company customer survey. The data was ugly: 7 positive, 11 negative data points. Jira specifically called out as the weak link in the portfolio. Confluence, Loom, and Rovo came through stronger.
Stock is off 63% from its 52-week high and down 52% YTD, now trading at $77.79. Average PT is $117.50 (range $95-$480 — that $480 is from a bull case that feels increasingly stale). The survey doesn’t change the fundamental cloud migration / AI narrative (Bernstein, Truist, Piper still constructive post-Team 26), but it’s a real-time pulse check that echoes the churn concerns that have driven the multiple compression.
“Jira appears to be the weak link in Atlassian’s product lineup.”
Not a catalyst call either way, but if you’re long TEAM, that line is worth staring at. Jira is the core. Confluence/Rovo/Loom are upsells. If the anchor product is leaking, the cross-sell math gets harder.
FBN finally woke up. PT to $330 (from a dusty $200) but the stock is already trading at $352 — so the target is actually below market. Thesis is straightforward: strong Q3 print, sector multiple expansion, and 41 upward EPS revisions. The call: strong results, but FBN explicitly flags "this sharp advance might lead to some profit-taking."
"This sharp advance might lead to some profit-taking."
Not sure we can read too much into a PT that's already underwater relative to the stock. FBN is playing catch-up, not breaking new ground. The stock is up 85% in six months and 60% in the month before the print — momentum is clearly priced in. Bull case rests on sustained 19.5% revenue growth and AI-driven demand (Piper Sandler flagged this after mgmt meetings). Bear case: the easy multiple has been taken, and FBN's own caution suggests limited upside from here without a fresh catalyst.
Wells Fargo upgrades AEIS to Overweight — not because the business is ripping, but because it’s massively underperformed. Stock +16% in Q2 vs SOX +88% and peer median +93%. That’s the kind of divergence that gets PMs interested on a relative-value basis if the thesis is turning.
The upgrade hinges on one catalyst: Wells expects AEIS to raise its 2026 semi and data center guidance when it prints Q2 earnings later this quarter. If they do, the catch-up trade is obvious — the stock has been pricing in stagnation, not acceleration.
"We expect the company to raise its 2026 semiconductor and data center growth expectations when it reports second-quarter earnings later this quarter."
R/r looks skewed to the upside here. You’re getting paid to be patient on a name that’s been left for dead while the whole space ran 90%+ without it.
THE BUY-THESIS IS NOW A FUNDING-THESIS. Freedom Broker cuts PT to $210 (from $230) but keeps Buy — the stock is down 10.5% in a week, the worst since dot-com, after the 10-K revealed D/E at 4.46 and $167B of debt. The narrative has flipped: demand is not the question; can they fund the build, convert the $77B cRPO into cash, and defend the credit rating? Management leans on prepaid/customer-funded structures, but the market is pricing in execution risk.
"The investment question has shifted from whether demand exists to whether Oracle can fund the build, convert the backlog into recognized revenue and cash, and defend its credit standing."
One article, one take: Freedom Broker sees execution as necessary but not sufficient to re-rate. The stock will trade on conversion and funding proof points — not cloud growth prints. (Evercore’s Outperform note on the $77B cRPO is a supporting data point, not a competing call — same thesis, different confidence.)
Goldman says Buy, stock is down 83% from highs — but they see a near-term floor from Make monetization. GS reiterated $30 target after Config, arguing Figma is becoming the "control layer" for product development. Seat counts stable-to-growing, AI credit consumption ramping post-March monetization. The snag: gross margin pressure, evolving competition, and a CEO insider sale that spooked the market.
"The most likely path for the stock is up near term given new products and Make monetization, though it may be challenging for the stock to move sustainably higher in the face of ongoing gross margin pressure and evolving competition."
Key detail from customer convos: prototyping is migrating outside Figma for non-designers, but workflows still converge back into Figma for iteration and handoff. Make’s functionality has improved "meaningfully" since launch — that's the lever GS is betting on.
The bull case: AI-driven seat expansion + Make consumption = revenue acceleration. Citi and William Blair are in that camp. The bear case: Anthropic competition, CEO selling $4.4M stock (pre-planned, but optics are horrid), and margins heading south. Findell wants cost cuts and board governance changes. Stock at $19 — 50% off YTD, 83% off the high — is pricing in a lot of pain, but the narrative hasn't flipped yet.
THE EXCASH CASH THESIS IS DEAD — or at least shelved. DA Davidson pulls OneSpan from its STAMPEDE "Excess Cash" list after management burned through $43M of the balance sheet since August (buybacks + dividend + $34.6M Build38 acquisition). Cash now $49.8M vs $92.9M Q2'25. No more dutch auction or special dividend expected near-term. Neutral, $12 PT unchanged.
"We no longer see another dutch auction or one-time special dividend as likely in the near term given the lower cash balance."
FCF yield still 9%, dividend yield 3.6%, and a fresh $50M buyback authorization keeps the lid on downside ($0.45 EPS beat in Q1 helped). But the rate of change on cash deployment is negative — less dry powder for M&A that could reaccelerate organic ARR. Feels like a value trap unless they find a needle-moving deal. Not actionable here.
Treading water at $21.95 despite a parade of post-Q1 PT bumps. Truist holds at $23 (Buy) with a cautious tone — wants to see if the new CEO's leadership overhaul actually sticks. Mizuho went to $32, Rosenblatt to $29, even Jefferies grudgingly lifted to $21. The consensus? Q1 beat was real, subscription growth accelerated for the second straight quarter ( +13% ), and backlog conversion is running faster than expected. But the stock can't seem to break out.
The real story is the executive shakeup that just went final on June 29 — new CTO, new CSO, plus Amit Mathradas (CEO since Feb) now has his full team. Truist calls this the "most comprehensive changes" since he took over. That's not a nothing-burger.
"Truist said the leadership changes represent the most comprehensive changes since Mathradas’s appointment. The firm will monitor whether the newly established executive team can help bolster Five9’s sales strategy, execution and product innovation."
So the bull case is baked into the numbers (Piotroski 9, "GREAT" financial health, accelerating subs). The bear case is execution risk — new faces, new dynamics, and the market wants proof before rerating the multiple. PT range now $21–$32, which tells you how wide the r/r split is. We're watching the next earnings call for the "lay the groundwork" narrative. If the new crew shows up with conviction, FIVN could squeeze higher. If not, $21 support gets tested again.
Raymond James starts AMPL Strong Buy, $10 PT (30% upside). They see risk/reward finally attractive after the 35% six-month haircut. Call the multiple “overly punitive” — AI software compression plus execution noise created the setup. Now they point to organic growth reacceleration, better retention, and stronger forward visibility. They think Street estimates are too low through FY27 and that the downside case (a broken software outcome) is unlikely given the behavioral data moat in the agentic era.
“Conservative estimates could push numbers higher through fiscal year 2027. Downside scenarios would imply a broken software outcome — that appears unlikely if Amplitude’s behavioral data foundation and action-oriented platform remain relevant in the agentic era.”
Piper Sandler already at Overweight / $9 — so this isn’t a solo call. The 1Q beat (rev $93.5M vs $92.9M) and raised FY guide to 16.5% y/y growth (from 14.8%) give the narrative some concrete support. The Statsig/OpenAI partnership helps the product story. Worth watching if the reacceleration holds.
Buy the vertical integration story. Needham keeps Buy / $120 PT after the $8B Iridium acquisition closed. This isn't just a bolt-on — it makes RKLB a self-launching satcom provider with launch, manufacturing AND a 60-satellite L-band constellation. Iridium shares already up 217% YTD so the market gets it, but the thesis is now about NEXT GEN services (8 MHz of spectrum for global voice/data) and immediate FCF accretion.
"The deal positions Rocket Lab as what Needham describes as a self-launching space company combining launch capabilities with satellite manufacturing and communications services."
The mechanicals matter. $54/share bogey on the cash component, RKLB stock as the rest. Needham's key call: this adds recurring services revenue to what was primarily a launch/build book — fundamentally changes the revenue mix and margin profile. The combined entity is now the #2 global launch provider (behind SpaceX) with a built-in anchor customer for future launches. Spectrum is the hidden asset here — L-band is mission-critical for enterprise/gov, not easily replicable. Not sure we can read too much into the 9604 module launch and Mlink testing given deal timing, but the IoT tailwind is real. PMs should watch the near-term dilution math vs. the long-term recurring revenue story.
EVERCORE STAYS OUTPERFORM, $150 PT — BUT THE STORY IS NOW ABOUT NEAR-TERM EXECUTION, NOT AI DREAMS. Stock at $99.28 (down 51% in a year), and the market is done giving credit for 2030 visions. All eyes on Q2 cRPO: guided ~19.5% constant currency, but that includes Moveworks and Armis. Strip those out and you're looking at low-to-mid 17% organic. The bar is low but fragile.
Evercore says 20-20.5% organic constant-currency cRPO would be "adequate" — 21%+ actually shifts the narrative on deceleration. The Financial Analyst Day laid out a $30B subscription revenue path by 2030 (17.5% CAGR), but that's not the derisking event bulls need. They need proof the base business isn't softening under federal headwinds.
"Investors will focus on whether organic current remaining performance obligations growth stabilizes as federal pressure eases and AI adoption builds."
Key tension: organic vs. inorganic. If Q2 prints 19.5% headline but organic is 17%, that's a miss on quality. If organic hits 21%, the stock rips. R/r skewed to upside if you think the Street is already pricing in the worst.
Guggenheim upgrades CRM to Buy from Neutral with a $228 PT — that's 46% upside. The call is pure valuation: 3.7x recurring revenue, 11x EV/NTM FCF, 18.2x P/E with a PEG of 0.46. Stock is DOWN 41% YTD on "SaaSpocalypse" fears. The firm doesn't buy the Armageddon narrative.
They see a company that may not grow much but also won't decline into perpetuity. The current price implies 5% annual shrinkage forever — that's the bet they're fading.
"While we view AI as a significant risk and see Salesforce as a company likely to be negatively impacted by the advent of Agentic AI, the Armageddon scenario currently priced into the stock is misaligned with reality."
Not a bull case on product or AI traction (still zero visibility). Just a valuation catch-up trade. 5x EV/NTM recurring revenue on the $228 target. We'd frame this as low r/r on the downside, not a slam dunk upside — but the valuation floor is finally getting recognized.
Wedbush goes long. Initiates Outperform, $190 PT (11% upside from $170.86). They see a hyperscaler in the making — vertically integrated across launch, connectivity, AI infra. The real game is Starlink becoming a telco bridge.
"Starlink holds less than 1% share of the global telecom and broadband market while building out its direct-to-device cellular services."
Key numbers: 12M Starlink subs (as of June 5), ~$66 ARPU, $19.3B LTM revenue, 49% gross margin. Not profitable this year per analysts, but Wedbush’s SOTP values the whole thing at ~$2.48T enterprise value on FY28E. Heavy weighting on Starlink recurring rev + V3 capacity expansion.
Other houses chiming in. KeyBanc started Sector Weight (neutral-ish, no price target disclosed). Fitch slapped a BBB+ on the new unsecured notes (proceeds repay $20B bridge loan). S&P at BBB stable. The IPO raised $86B and printed a $2.4T market cap — context for why $190 PT feels measured.
Starship carrying 60 sats per launch (vs Falcon 9's 27) reinforces the cost-per-kg flywheel. Reusability is the moat, not just hype.
Bottom line: You're buying a monopoly on orbit with an option on AI infrastructure. The ~11% upside isn't the story — the rate of change in satellite economics and DTC cellular is. Watch the financing round for AI capex; that's the next catalyst.
Verdict: The beat-and-raise quarter is real, but the Q3 guide whiff on deal timing keeps the narrative messy. Stock ripped 12% last week anyway — market is buying the full-year raise and the PEG ratio of 0.27, not the near-term lumpiness. D.A. Davidson sticks with Buy and a $40 PT, leaning on durable SaaS growth and new customer momentum.
"Progress Software reported second-quarter fiscal 2026 results that exceeded expectations, driven by broad-based demand. Favorable deal timing contributed to the outperformance."
That "favorable timing" giveth in Q2 and taketh away in Q3. The guide below consensus is the obvious speed bump, but the full-year revenue raise tells you the underlying demand trend is intact. SaaS revenue growth is holding, gross margins are an 85.6% fortress, and net new customer additions plus expansions are both positive. After-hours dip on a beat — classic positioning noise. If the PEG stays sub-0.3x, value PMs will keep poking around.
Initiating Buy at Craig-Hallum with a $36 PT gets our attention, but the stock is still reeling from a horrid Q3 miss. AVNW trades at 7.5x FY27 EPS vs. a 13x target — that’s a 73% discount baked in for execution risk. The thesis hinges on three growth catalysts that could independently move the needle, but the near-term margin and revenue volatility are real.
The firm sees a clean story: $450M in NOLs to shield future income, an improving competitive setup (Nokia exiting microwave, Huawei bans in Europe), and three specific demand drivers. The biggest swing factor is BEAD — $100M multi-year revenue potential starting late CY26. But the Q3 miss was ugly: organic revenue down $9M from Middle East project delays and Tier 1 pull-forwards, gross margins cratering from 35.8% to 29.4%. That’s the risk you’re being paid to take.
“Multi-dwelling unit fixed wireless represents a new product and market for Aviat, with initial orders exceeding the size of its largest historical project.”
Bottom line: The risk/reward works if you believe the Q3 stumble was lumpy, not structural. At 7.5x earnings with a clean balance sheet and a catalyst pipeline that includes BEAD, Nokia's exit, and MDU FWA, this is a high-beta turnaround play that could double. Just don't expect a straight line.
UBS stays neutral on AAPL – survey data shows a mixed bag with no clear catalyst. The $296 target implies zero upside from $292. They parsed 7,500 smartphone users across 5 markets. US purchase intent up ~300bps YoY to ~20% (solid). China down ~100bps to ~15% (problem). And the AI upgrade narrative? Fading fast — only 24% say they'd upgrade sooner for Apple Intelligence features, down 500bps. Meanwhile 31% say no impact, up 300bps. Not a recipe for multiple expansion at 35.5x earnings.
"Total net interest in an Apple foldable declined ~100bps from the prior survey to ~39%, though the favorability spread over a foldable smartphone rose ~600bps."
Foldable interest dropping is a yellow flag, though the spread improvement suggests those who do want one really want one. Mixed. The iPhone age in the base declined slightly (22.9 months, down 0.8) but remains near survey highs — replacement cycle not accelerating meaningfully. Valuations are stretched against this backdrop. 26 analysts revised EPS up recently, but UBS isn't budging. Hard to chase here.
Baird extends its Bullish Fresh Pick designation through March 2027. That's a four-quarter extension on a name they already love at $110 PT. The call: RBRK is an underappreciated AI beneficiary with 46% revenue growth to $1.42B, 81% gross margins, and a growth runway still above 20%. Operating leverage is improving, FCF is kicking in.
"We view the stock’s valuation as attractive and consider Rubrik an underappreciated beneficiary of artificial intelligence trends."
Other analysts aren't arguing — Cantor, Truist, and DA Davidson all sit at Buy/Overweight with PTs in the $90-95 range. The Analyst Day narrative is solid: higher gross margin targets, new Flex licensing, and a fresh hire from ServiceNow to push channel partnerships. Consensus beat by 5.7% on revenue, ARR printed $103M net new vs. $85.5M expected. The growth machine is humming. Valuation isn't cheap, but 20%+ organic growth with expanding margins and a narrative hook into AI data security is a combo PMs should chase.
Guggenheim upgrades to Buy. The call is pure valuation — 4.3x EV/NTM revenue vs. security peers at 11.6x, 8x free cash flow vs. peers at 35x. That’s a 43% upside target to $188 baked in. Only catalyst is the buyback: $2B expansion on May 11, and management has been aggressive. Fundamentals are still ugly — Q1 missed, Q2 will too, go-to-market transition is dragging a single-digit grower lower. But at 13x P/E and a 0.45 PEG, it’s pricing in zero improvement.
“The firm believes the stock trades materially below the intrinsic value of its recurring revenue and at a single-digit free cash flow multiple.”
Not much to love on the narrative side yet. The product news (AWS Sovereign Cloud, OpenAI integration, Bedrock AgentCore) is real but won’t move the needle near-term. This is a deep value trap until growth re-accelerates — but the buyback floor is thick. PMs looking for cheap software exposure with a capital return kicker should take a look. Just don’t expect alpha from the organic story anytime soon.
TYL is a consensus buy despite getting shredded - down 50% in the past year to $301. Multiple shops reiterated bullish post-Investor Day: Truist at $440, DA Davidson at $460, Citizens at $500. The bull case is 2026 EPS guidance raised +$150M buyback starting mid-June + long-term SaaS revenue growth. But the stock is pricing in zero margin for error. The near-term risk? Tough transaction comps and seasonal lumpiness. Truist trimmed Q2 estimates to better reflect that cadence but left full-year mostly intact.
"We maintain confidence in Tyler Technologies’ ability to execute against its strategic targets following the company’s Investor Day, marketing activities with management, and a follow-up discussion." — Truist